Publication Year: Year

KRAS-Targeted PROTAC Degraders are Broadly Efficacious Against KRAS Dependent Tumor Models

High throughput screening techniques to inform on compound liability and solubility to advance the PROTAC® platform

A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – Poster Presentation

A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – PLS

Structural insights into PROTAC®-induced proximity

The Arvinas PROTAC® Discovery Engine: Insights from Discovering & Developing Molecules That Induce Targeted Protein Degradation

PROTAC® Protein Degraders in the Clinic

ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Orally Administered PROTAC® Molecules Selectively Clear Pathologic Proteins in CNS & Muscle

Outcomes in men with metastatic castration-resistant prostate cancer and tumors with certain androgen receptor (AR) mutations